The bill amends several sections of the West Virginia Code concerning controlled substance schedules, specifically targeting updates to the classifications of various drugs, including opiates, hallucinogens, and synthetic cannabinoids. It maintains fentanyl and carfentanil as Schedule II substances while incorporating various fentanyl analogs and derivatives into Schedule I. The legislation also introduces new language to clarify definitions and classifications, particularly for synthetic compounds that act as Cannabinoid receptor type 1 agonists and are not federally approved for medical use. This includes a comprehensive list of substances classified under Schedule I, II, III, and IV, ensuring that immediate precursors and derivatives are also regulated.

Additionally, the bill updates regulations for Schedule IV and Schedule V substances, specifically excluding human chorionic gonadotropin from regulation when used in nonhuman species, provided it is FDA-approved. It adds new substances to Schedule V, such as gabapentin and pregabalin, and clarifies conditions for combining narcotic drugs with nonnarcotic active ingredients. The bill aims to enhance regulatory oversight and public safety in response to the evolving landscape of drug use and is set to take effect 90 days after passage, on July 10, 2025.

Statutes affected:
Introduced Version: 60A-2-204, 60A-2-206, 60A-2-208, 60A-2-210, 60A-2-212
Engrossed Version: 60A-2-204, 60A-2-206, 60A-2-208, 60A-2-210, 60A-2-212
Enrolled Version: 60A-2-204, 60A-2-206, 60A-2-208, 60A-2-210, 60A-2-212